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Although transplantation of adult bone marrow mesenchymal stem cells (BM-MSCs) holds promise in the 
treatment for pulmonary arterial hypertension (PAH), the poor survival and differentiation potential of adult 
BM-MSCs have limited their therapeutic efficiency. Here, we compared the therapeutic efficacy of human 
embryonic stem cell-derived MSCs (hESC-MSCs) with adult BM-MSCs for the treatment of PAH in an animal 
model. One week following monocrotaline (MCT)-induced PAH, mice were randomly assigned to receive 
phosphate-buffered saline (MCT group); 3.0 ´  106 human BM-derived MSCs (BM-MSCs group) or 3.0 ´  106 
hESC-derived MSCs (hESC-MSCs group) via tail vein injection. At 3 weeks posttransplantation, the right ven-
tricular systolic pressure (RVSP), degree of RV hypertrophy, and medial wall thickening of pulmonary arteries 
were lower=, and pulmonary capillary density was higher in the hESC-MSC group as compared with BM-MSC 
and MCT groups (all p < 0.05). At 1 week posttransplantation, the number of engrafted MSCs in the lungs 
was found significantly higher in the hESC-MSC group than in the BM-MSC group (all p < 0.01). At 3 weeks 
posttransplantation, implanted BM-MSCs were undetectable whereas hESC-MSCs were not only engrafted in 
injured pulmonary arteries but had also undergone endothelial differentiation. In addition, protein profiling of 
hESC-MSC- and BM-MSC-conditioned medium revealed a differential paracrine capacity. Classification of 
these factors into bioprocesses revealed that secreted factors from hESC-MSCs were preferentially involved in 
early embryonic development and tissue differentiation, especially blood vessel morphogenesis. We concluded 
that improved cell survival and paracrine capacity of hESC-MSCs provide better therapeutic efficacy than 
BM-MSCs in the treatment for PAH. 
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an endothelin receptor antagonist and phosphodiesterase 
type 5 inhibitor, the only cure for this devastating disease 
is lung transplantation (4). This is nonetheless limited by 
a shortage of available donor organs and the risk of lung 
graft rejection (19). Recent experimental and clinical stud-
ies suggest that transplantation of bone marrow (BM)-
derived mesenchymal stem cells (MSCs) (3,15,16,24) 
may attenuate the progression of PAH and restore lung and 
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a life-threatening 
disease characterized by increased arterial medial thick-
ness, intimal fibrosis, and arteriolar occlusion of the pul-
monary circulation. These pathological changes result in 
progressive elevation of pulmonary arterial pressure, right 
ventricular (RV) failure, and death (26). Despite recent 
advances in pharmacological therapy, including the use of 
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heart function. However, there are several potential limi-
tations of using BM-MSCs. Firstly, BM-MSCs display a 
limited proliferative capacity and a large variability of cell 
quality derived from different donors. Secondly, during ex 
vivo expansion before possible therapeutic use, these cells 
quickly lose differentiation potential and the ability to pro-
duce protective factors (7,43). Importantly, survival capac-
ity and stem cell functions of BM-MSCs derived from aged 
or diseased donors (i.e., PAH) are profoundly impaired 
(15) and thus limit their therapeutic efficacy (12,34,44). 
Therefore, it is desirable to identify more therapeutically 
useful stem cells for more effective treatment of PAH.
Recently, we have derived functional MSC lines from 
human pluripotent stem cells (21,23). Compared with adult 
BM-derived MSCs, pluripotent stem cells-derived MSCs 
have a higher potential for proliferation and differentia tion. 
For instance, human embryonic stem cell-derived MSCs 
(hESC-MSCs) can be expanded in more than 25 passages 
without obvious senescence and also demonstrate an abil-
ity to differentiate into multiple cell types. On the other 
hand, adult BM-MSCs quickly become senescent after 
a short-term expansion (21). Similar to hESC-MSCs, 
human-induced pluripotent stem cell-derived MSCs (23) 
may also be an invaluable cell source in the treatment 
of PAH and overcome many disadvantages of using 
BM-MSCs. Nevertheless, the therapeutic efficacy of pluri-
potent stem cells-derived MSCs in PAH has not been deter-
mined yet. In this study, we demonstrated that pluripotent 
hESC- derived MSCs are superior to adult BM-derived 
MSCs in the attenuation of PAH induced by monocrotaline 
(MCT) injection. Compared with BM-MSCs, the greater 
therapeutic potential of hESC-MSCs might be attributed to 
their ability to survive longer after transplantation as well 
as the more robust capacity to promote pulmonary arterial 
regeneration via direct de novo vascular differentiation or/
and great paracrine mechanisms.
MATERIALS AND METHODS
Generation and Characterization of Human ES Cell 
Line-Derived Mesenchymal Stem Cells 
Clinically compliant MSCs derived from hESC lines 
have been described previously (21). In this study, MSCs 
derived from the HES-3 cell line (WiCell® Research 
Institute) were used as hES-3 cells have a great poten-
tial for cardiovascular differentiation (30). Briefly, a 
confluent 6-cm plate of hES3 cells was trypsinized on a 
gelatinized 10-cm dish containing enrichment of MSC 
outgrowth medium: Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Grand Island, NY) supplemented with 
10% serum replacement medium (Gibco), 10 ng/ml basic 
fibroblast growth factor (bFGF; Gibco), 10 ng/ml dimeric 
platelet-derived growth factor A and B chain (PDGFAB), 
and 10 ng/ml epidermal growth factor (EGF; Peprotech, 
Rocky Hill, NJ). One week after hES3 cells under above 
differentiation medium, the differentiating hES3 cells 
were harvested and sorted for CD24–CD105+ subpopu-
lation. The CD24–CD105+ cells were seeded in a 10-cm 
cultural dish with limiting dilution (1,000 cells/per 10-cm 
dish) and allow single cell-derived colonies to grow up. 
When colonies were formed and grown up, each clone 
was picked up and transferred to a six-well plate that was 
serially reseeded thereafter in 25 cm2 and 75 cm2. A total 
of four clone lines were achieved in this manner. Clones 
of hES3-MSC2 were selected for continuous cultures. 
MSCs derived from the hES-3 cell line (hESC-MSCs) 
were characterized by surface antigen profiling, adipo-
genesis, osteogenesis, and chondrogenesis studies (21). 
Oil red staining for adipocytes, Alizarin Red staining for 
osteocytes, and Alcian Blue staining for chondrocytes 
were used as standard techniques. Characterized human 
adult BM-MSCs were commercially acquired from 
Cambrex BioScience (Cat. No. PT-2501). All human 
materials used in this study were approved by the ethical 
committee of the University of Hong Kong.
Animal Model of PAH
PAH was induced in adult mice (ICR strain, provided 
by the laboratory animal unit of the University of Hong 
Kong) by intraperitoneal injection of MCT (6). In the 
negative control group, mice were injected with saline 
(n = 15). To establish the animal model of PAH and mini-
mize nonspecific acute lung injuries induced by overdose 
of MCT injection, three dosages of MCT (200, 400, and 
600 mg/kg) were tested in a pilot study. We observed no 
evidence of PAH in 200 mg/kg-treated group (n = 10) but a 
high mortality (70%) in 600 mg/kg-treated group (n = 10). 
As a result, we choose the dosage of 400 mg/kg in our 
experiment as previously reported (34) and confirmed the 
successful creation of an animal model of PAH by mea-
suring RV systolic pressure (RVSP) at 1 week following 
MCT administration (n = 15). A further group of animals 
were randomized to receive intravenous administration of 
(1) phosphate-buffered saline (PBS, MCT group, n = 15), 
(2) 3.0 ´  106 BM-MSCs (BM-MSCs group, n = 15), or 
(3) 3.0 ´  106 hESC-MSCs (hESC-MSC group, n = 15) 
via tail vein injection 1 week following administration 
of MCT. A subgroup of mice in each group (n = 6) were 
sacrificed 1 week following transplantation to determine 
cell retention and survival. The remaining animals (n = 9 
each group) were kept for 3 weeks following transplanta-
tion when final hemodynamic assessment was made. All 
animals were treated with 15 mg/kg/day cyclosporine for 
2 days before and daily after transplantation. In addition, 
3.0 ´  106 BM-MSCs were also injected into three severe 
combined immunodeficient (SCID, provided by the labo-
ratory animal unit of the University of Hong Kong) mice 
via tail vein injection. After 3 weeks of cell injection, 
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SCID mice were sacrificed for histological examina-
tion. All experiments were approved by the Committee 
on the Use of Live Animals in Teaching and Research 
(CULTAR) at the University of Hong Kong. 
Hemodynamic Assessment 
At 3 weeks posttransplantation, mice were anesthe-
tized (induction with intraperitoneal injection of 100 mg/
kg of ketamine and 20 mg/kg of xylazine) and mechani-
cally ventilated. Blood pressure was measured by the tail-
cuff method using a noninvasive automatic blood pressure 
recorder (Visitech System BP-2000 Blood Pressure 
Analysis System, USA). Average values of arterial 
systolic BP (SBP) were derived from three consecutive 
measurements. A 1.4-Fr high-fidelity microtip catheter 
connected to a pressure transducer (Millar Instruments, 
Houston, TX, USA) was inserted into the RV cavity 
via the right internal jugular vein to record RVSP using 
the PowerLab system (AD Instruments, Inc., Colorado 
Springs, CO, USA).
Assessment of RV Hypertrophy 
Mice were sacrificed following hemodynamic assess-
ment for histological and immunohistochemical exami-
nation. After removal of the heart, the RV free wall was 
excised from the left ventricular (LV) wall and the inter-
ventricular septum. The ratio of the weight of the RV to 
LV plus septum [RV/(LV + septum)] was calculated as an 
index of RV hypertrophy (18).
Polymerase Chain Reaction (PCR)
Genomic PCR for human Alu-sx repeat sequences and 
mouse c-mos repeat sequences were performed as previ-
ously described (21). Telomerase activity was performed by 
Telomeric Repeat Amplification Protocol (TRAP) as des-
cribed previously (21,23) and according to manufacturer’s 
recommendations (Allied Biotech, Cat. No. MT 3010). Each 
sample was analyzed at least in duplicates. Telomerase activ-
ity was expressed relative to BM-MSCs. Reverse transcrip-
tion (RT)-PCR for human-specific fibroblast growth factor 2 
(FGF2), von Willebrand factor (vWF), vascular endothelial 
growth factor (VEGF), and vascular endothelial growth fac-
tor receptor 2 (Flk-1) was performed in a total volume of 
20 ml with 20 nmol of each primer. The primers were as fol-
lows: hvWF: F5¢-TGACGGTGAATGGGAGACTGG-3¢, 
R5¢-GCATGAAGTCATTGGCTCCGTTC-3¢;  hVEGF: 
F5¢-GCAGAAGGAGGAGGGCAGAATC-3¢,  R5¢-CACT 
CCAGGCCCTCGTCATT-3¢; hFGF2: F5¢-GAAGA 
GCGACCCTCACATCAAG-3¢, R5¢-CTGCCCAGTTCGT 
TTCAGTG-3¢; GADPH: F5¢-GTCTTCACCACCATG 
GAGAAGG-3¢, R5¢-GCCTGCTTCACCACCTTCT 
TGA-3¢; VEGFR2 (also named Flk-1): F5¢-GTGACCAA 
CATGGAGTCGTG -3¢,  R5¢-CCAGAGATTCCATG 
CCACTT-3¢.
Histological Analysis, Immunohistochemical Staining, 
and Cytokine Assays
The lungs were fixed with 10% buffered formalin 
and embedded in paraffin, then sectioned to 5-μm slides, 
and stained with hematoxylin and eosin. Morphometric 
analysis was performed on pulmonary muscular arteries 
whose external diameter ranged from 25 to 100 μm, using 
a color digital camera mounted on a computer-interfaced 
light microscope. Medial wall thickness was measured as 
the distance between the external and internal elastic lam-
ina of each artery using a calibrated eyepiece micrometer; 
external diameter was measured as the diameter of the 
external lamina. The percentage medial wall thickness of 
each artery was calculated using the following: % medial 
wall thickness = 2 ´  medial wall thickness/external diam-
eter ´ 100. For each lung section, 20 pulmonary arteries 
were measured, and the average value calculated (29). 
Standard procedures were applied for immunohis-
tochemical staining (22). The lung sections were prepared 
with a cryostat and immunostained with goat anti-CD31 
(Santa Cruz, SC-1506), human nuclear antigen (HNA) 
polyclonal antibody (MAB1281, Chemicon). The primary 
antibodies were incubated overnight at 4°C with a 1:100 
dilution. Then secondary antibodies with a 1:200 dilution 
were used against the primary antibodies. For fluorescent 
immunostaining, sections were analyzed using a deconvo-
luted fluorescent microscope and Metamorph software.
For simultaneous detection of BM-MSC- and hESC-
MSC-derived paracrine factors, serum-free cell culture 
supernatants of BM-MSCs and hESC-MSCs were har-
vested, filtered through a 0.22-μm filter, and concentrated 
(38). A total of 200 μl of conditioned or nonconditioned 
medium was assayed for the presence of cytokines and 
other proteins using RayBio® Cytokine Antibody Arrays 
according to the manufacturer’s instructions (RayBiotech, 
Norcross, GA, Cat. No. AAH-BLG-1-4). Quantitative 
human cytokines were measured using customized Bio-
Plex cytokine assays (Bio-Rad Laboratories, Hercules, 
CA, Cat. Nos. M50007VNJK and MF00038C9E) accord-
ing to the manufacturer’s instructions.
Statistical Analysis
Data are expressed as mean ± standard derivation. Sta-
tistical analysis was performed with ANOVA followed by 
the Bonferroni test for multiple comparisons between dif-
ferent study groups. A value of p < 0.05 was considered 
statistically significant.
RESULTS
Characterization of hES-3-Derived MSCs
Unlike its parental hES-3 cell line, the hES-3 cell line-
derived MSCs (hESC-MSC) were highly similar to adult 
BM-MSCs in morphology (Fig. 1A, i). Adipogenesis was 
highly efficient with oil red droplets observed in >80% 
2228 ZHANG ET AL.
of the hESC-MSCs (Fig. 1A, ii). Osteogenesis was effi-
cient with >80% cells had Alizarin Red staining for cal-
cium deposition (Fig. 1A, iii). Chondrogenesis was also 
efficient with >90% of cells producing proteoglycans in 
extracellular matrix as detected by Alcian Blue staining 
(Fig. 1A, iv). These hESC-MSCs also expressed similar 
surface antigen profiling, which defined BM-MSCs, that 
is, CD29+, CD44+, CD49a and e+, CD73, CD90+, CD105+, 
CD271+ and CD34–, CD45–, CD133– as demonstrated 
by fluorescence-activated cell sorting (FACS) analysis 
(Fig. 1B). These hESC-MSCs were not contaminated with 
undifferentiated hESCs as they are negative for hESC 
Figure 1. (A) The typical morphology of human embryonic stem cell line hES-3-derived mesenchymal stem cells (MSCs) (hESC-MSCs). 
(i) Scale bar: 20 mm. Oil Red staining for adipogenesis. (ii) Scale bar: 200 mm. Alizarin Red staining for osteogenesis. (iii) Scale bar: 200 mm. 
Alcian Blue staining for chondrogenesis. (iv) Scale bar: 200 mm. (B) Surface markers profiling by fluorescence activated cell sorting 
(FACS) in hES3-MSC cultures for CD29, CD44, CD49a, CD49e, CD73, CD90, CD105, CD271, CD34, CD45, CD133, and TRA-81. 
(C) Differential telomerase activity among bone marrow (BM)-MSCs, hESC-MSCs, and hES-3 (*p < 0.001 vs. BM-MSCs; #p < 0.001 vs. 
hESC-MSC). (D) Transcript levels of pluripotency-associated gene Oct4 were measured by quantitative reverse transcription-polymerase 
chain reaction (PCR) and normalized to that of hES-3 (*p < 0.01 vs. hES-3). (E) Following exposure of cells to endothelial differentiation 
medium for 3 days, transcript levels of endothelial differentiation marker Flk-1 were measured among hESCs, hESC-MSCs, and BM-MSCs 
by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and normalized to that of hES-3 (*p < 0.001 vs. BM-MSCs). 
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surface marker TRA-81 (Fig. 1B). Furthermore, hESC-
MSCs were highly expandable up to 30 passages (90 pop-
ulation doublings) without obvious loss of self-renewal 
capacity and constitutively express surface antigens of 
multipotent MSCs. 
To understand the molecular basis of the high pro-
liferation potential of hESC-MSCs, telomerase activity 
was compared among BM-MSCs, hESC-MSCs, and 
hESCs. It revealed more than 10-fold higher level of 
telomerase activity in hESC-MSCs (passage 25) than in 
BM-MSCs (passage 5) (Fig. 1C). This might account 
for the greater capacity of cell proliferation in hESC-
MSCs than BM-MSCs. Above passage 40, random chro-
mosomal aberrations were observed by karyotyping. 
Therefore, these hESC-MSCs were chromosomally sta-
ble up to at least passage 40 (120 population doublings), 
and thus, hESC-MSCs below passage 30 were used for 
this study.
Expression of pluripotency-associated genes was gen-
erally reduced in hESC-MSCs. For example, expression 
of pluripotent gene Oct4 was significantly reduced 10,000 
times compared to hES-3 cells (Fig. 1D). To confirm the 
loss of pluripotency in hESC-MSCs, 1 × 106 hESC-MSCs 
were subcutaneously transplanted into SCID mice. The 
transplanted hESC-MSCs did not appear to survive or 
engraft into the normal recipient tissue (data not show). 
The endothelial differentiation potential of BM-MSCs, 
hESC-MSCs, and hESCs was compared by measuring the 
expression level of human VEGFR2 (also named Flk-1) 
with qRT-PCR. As shown in Figure 1E, the expression 
level of Flk-1 in hESC-MSCs was significantly higher 
than those in BM-MSCs or hESCs. 
Hemodynamic Changes of PAH and MSC 
Transplantation
The experimental protocol was shown in Figure 2A. 
To determine the effects of MCT administration on pul-
monary and systemic circulation, the RVSP and SBP of 
mice were measured. Compared with the control group 
(27.4 ± 0.70 mmHg), RVSP was significantly increased 
at 1 week (40.24 ± 3.32 mmHg, p < 0.05) and 4 weeks 
(59.12 ± 4.32 mmHg, p < 0.01) following MCT adminis-
tration. This confirmed successful induction of PAH by 
MCT administration (Fig. 2B). Similarly, the degree of 
relative pulmonary hypertension measured by the ratio of 
RVSP/SBP was also significantly increased at 4 weeks 
in the MCT group as compared with control (Fig. 2C) 
(p < 0.01). However, there were no difference in SBP 
between the control and study mice at 4 weeks following 
MCT administration (Fig. 2D) (p > 0.10), suggesting that 
MCT-induced vascular injuries mainly limited in pulmo-
nary circulation. 
Since elevated RVSP was evident at 1 week follow-
ing MCT administration, we decided to examine the 
Figure 2. Intravenous transplantation of hESC-MSCs or BM-MSCs 
attenuated monocrotaline (MCT)-induced pulmonary arterial hyper-
tension (PAH) and right ventricular hypertrophy. (A) Schematic chart 
shows introduction of PAH and transplantation of hESC-MSCs or 
BM-MSCs into a PAH mouse model. (B) Right ventricular systolic 
pressure (RVSP) measured at week 1 and week 4 after MCT admin-
istration. The increased RVSP was detected after 1 week of MCT 
treatment (*p < 0.01 vs. control group; # p < 0.01 vs. MCT 1 week). 
(C) RVSP/SBP (systolic blood pressure; relative pulmonary hyper-
tension) ratio was measured at week 4 among mice who received 
MCT, BM-MSC, or hESC-MSC treatment (*p < 0.01 vs. control 
group; # p < 0.01 vs. MCT group; †p < 0.01 vs. BM-MSC group). 
(D) At week 4 after MCT administration, blood pressure (BP) was 
determined and no major difference was observed among mice who 
received MCT, BM-MSC, or hESC-MSC treatment.
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protective effect of MSC therapy during this early stage 
of MCT-induced PAH. Therefore, BM-MSCs or hESC-
MSCs were injected intravenously 1 week after MCT 
administration. At 3 weeks posttransplantation (4-week), 
RVSP was significantly reduced by 27.3% and 45.3%, 
respectively, in the BM-MSCs and hESC-MSCs groups, 
compared with MCT group (Fig. 3A, i–ii). Similarly, the 
ratio of RVSP/SBP was also significantly decreased at 4 
weeks in the hESC-MSC group as compared with MCT 
group (Fig. 2C) (p < 0.01). Furthermore, RVSP (Fig. 3A) 
(p < 0.01) and ratio of RVSP/SBP (Fig. 2C) (p < 0.01) 
were also significantly lower in the hESC-MSC group 
compared with BM-MSC group.
Histological Changes of PAH and MSC Transplantation
As shown in Figure 3B, MCT-induced elevated 
RVSP was associated with histological evidence of RV 
hypertrophy. At 4 weeks, the MCT group had a signifi-
cantly higher RV/(LV + Septum) ratio compared with 
the control group (Fig. 3B, i–ii) (p < 0.01). At 3 weeks 
posttransplantation (4-week), the RV/(LV + septum) 
ratio was significantly reduced by 15.6% and 26.8% in 
the BM-MSCs and hESC-MSCs groups, respectively, 
compared with MCT group (Fig. 3B) (p < 0.01). This 
indicates reduced RVSP by BM-MSC or hESC-MSC 
transplantation attenuated RV hypertrophy in MCT-
induced PAH mice. The RV/(LV + septum) ratio was also 
significantly lower in the hESC-MSC group compared 
with the BM-MSC group (0.23 ± 0.02 vs. 0.26 ± 0.01; 
p < 0.01), suggesting that hESC-MSCs are superior 
to BM-MSCs in attenuating RV hypertrophy in MCT-
induced PAH mice (Fig. 3B).
To examine the potential therapeutic mechanisms of 
MSCs, we analyzed the anatomic changes in pulmonary 
arteries at 4 weeks. Morphometric analysis of lung tis-
sues revealed a significant pulmonary vascular remod-
eling in MCT-treated mice (Fig. 4B). Compared with 
the control mice (Fig. 4A), MCT-treated mice exhibited 
Figure 3. Intravenous transplantation of hESC-MSCs or BM-MSCs attenuated MCT-induced right ventricular hypertrophy. 
(A) (i) Right ventricular systolic pressure (RVSP) was measured in mice who received different treatments at week 4 following MCT 
administration (*p < 0.01 vs. control group; # p < 0.01 vs. MCT group; †p < 0.01 vs. BM-MSC group). (ii) Representative photographs 
show obvious differences in RVSP among mice who received different treatments. (B) (i) The ratio of right ventricular to left ven-
tricular plus ventricular septum (RV/LV + S) weight at week 4 (*p < 0.01 vs. control group; # p < 0.01 vs. MCT group; †p < 0.01 vs. 
BM-MSCs group). (ii) Representative photographs show right ventricular hypertrophy following exposure to MCT, partially reversed 
by BM-MSC or hESC-MSC transplantation. Scale bar: 2.5 mm. 
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significantly greater vessel wall thickness characterized 
by an excessive muscularization of distal pulmonary ves-
sels and increased vascular stenosis (Fig. 4B, ii–iv). In 
contrast, BM-MSC or hESC-MSC transplantation signif-
icantly attenuated MCT-induced medial wall thickening 
of the pulmonary arteries (Fig. 4C, D). At 3 weeks after 
transplantation (4-week), the percentage of medial wall 
thickness was significantly reduced by 23.9% and 44.1% 
in the BM-MSC and hESC-MSC groups, respectively, com-
pared with the MCT group (Fig. 4E) (p < 0.01). The per-
centage of medial wall thickness was also significantly 
lower in the hESC-MSC group compared with BM-MSC 
Figure 4. Transplantation of hESC-MSCs or BM-MSCs alleviated MCT-induced pulmonary artery remod-
eling and enhanced density of pulmonary microvascular beds. Through A–D, representative low and high 
magnification photographs show differential pulmonary vascular changes among mice who received differ-
ent treatment. (A) (i–ii) Control mice. (B) (i–iv) Mice with MCT treatment displaying complex pulmonary 
vascular lesions: (ii) Higher-magnification photomicrographs of medial wall thickening. (iii) Lumens of 
small pulmonary arteries were almost blocked caused by an excessive muscularization. (iv) Severe luminal 
stenosis with complex vascular lesion. (C) (i–ii) The medial wall thickening in small pulmonary arter-
ies was partially attenuated by BM-MSC transplantation. (D) (i–iii) Medial wall thickening was signifi-
cantly reduced by hESC-MSC treatment. (E) The percentage medial wall thickness of each artery with an 
outer diameter ranging between 25 and 100 mm was analyzed. In each mouse, 30 vessels were counted 
per lung section (*p < 0.01 vs. control group; #p < 0.01 vs. MCT group; †p < 0.01 vs. BM-MSCs group). 
(F) Relationship between arterial thickness and right ventricular systolic pressure (RVSP). Scale bar: 50 mm. 
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group (Fig. 4E) (30.1% ± 2.4% vs. 40.9% ± 5.9%; p < 0.01). 
In addition, the percentage of medial wall thickness was 
significantly and positively associated with elevated RVSP 
(Fig. 4F) (r2 = 0.86, p = 0.006). 
Next, we investigated the endothelial protection by MSC 
transplantation on MCT-induced pulmonary endothelial 
damage (14). Compared with the control group (Fig. 5A), 
immunostaining with anti-CD31, an endothelial marker, 
revealed significantly decreased CD31-positive pul-
monary arterial/arteriolar vessels in the lung tissue of 
MCT-treated mice  (Fig. 5B). However, after 3 weeks of 
transplantation (4-week), the number of CD31-positive 
arterial/arteriolar vessels had tripled in the BM-MSCs 
and quintupled in the hESC-MSCs group, respectively, 
compared with the MCT group (Fig. 5C–E) (p < 0.01). 
Importantly, the number of CD31-positive arterial/
Figure 5. Representative photographs show differential microvascular beds covered by CD31-
positive endothelial cells among mice who received different treatment. (A) Control mice. (B) MCT 
mice (*showing medial wall thickening in a small pulmonary artery). (C) BM-MSC mice. (D) hESC-
MSC mice. (E) Quantitative analysis of CD31-positive arterial/arteriolar vessels numbers. Five mice 
from each group were analyzed, six sections were randomly collected from each mouse and viewed 
for positive CD31 arterial/arteriolar vessels numbers (*p < 0.01 vs. control group; # p < 0.01 vs. MCT 
group; †p < 0.01 vs. BM-MSCs group). (F) The association between CD31 arterial/arteriolar vessels 
density and right ventricular systolic pressure (RVSP). Scale bar: 50 mm. 
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arteriolar vessels was significantly higher in the hESC-
MSCs group compared with BM-MSCs group (Fig. 5E) 
(105 ± 7/mm2 vs. 189 ± 8/mm2, p < 0.01), indicating hESC-
MSCs were superior to BM-MSCs in preventing endo-
thelial damage in MCT-induced PAH mice. Furthermore, 
the density of CD31-positive arterial/ arteriolar vessels 
was significantly positively associated with elevated 
RVSP (Fig. 5F) (r2 = 0.83, p = 0.006).
Retention and Survival of MSC After Transplantation 
The retention and survival ability of hESC-MSCs or 
BM-MSCs in lung tissue with PAH was examined 1 week 
(2-week) and 3 weeks (4-week) after transplantation. The 
transplanted human cells were detected with immunostain-
ing for anti-HNA, PCR for human DNA repeat sequences 
Alu-sx, and reverse transcription PCR for detection of 
human-specific growth factors. 
One week after transplantation (2-week), immuno-
staining of lung tissue with anti-HNA revealed both 
hESC-MSCs (Fig. 6A, i–iii) and BM-MSCs (Fig. 6B, 
i–iii) were mainly located at pulmonary vessels and 
nearby extravascular parenchyma. Reverse transcription-
 PCR analysis revealed gene expression of human vWF 
as well as human growth factors VEGF and FGF2 
in the lung tissue from hESC-MSCs and BM-MSCs 
groups, but not in the MCT or control group (Fig. 6C). 
Furthermore, the Bio-Plex cytokine assays demonstra-
ted the presence of human-specific cytokines VEGF, 
FGF2, and stem cell factor (SCF) in mice lung protein 
extracts from the hESC-MSC and BM-MSC groups 
(Fig. 6D). These findings suggest that some trans planted 
MSCs released cytokines and underwent endothelial 
differentiation in response to MCT-induced pulmonary 
vascular injury. Notably, the number of anti-HNA- 
 positive cells retained in the lung tissue 1 week post-
transplantation was significantly higher in the hESC-
MSC group than the BM-MSC group (310 ± 40/mm2 
 vs. 105 ± 10/mm2, p < 0.01).
At 3 weeks after transplantation (4-week), the num-
ber of anti-HNA-positive cells retained in the lung tis-
sue was significantly decreased in the hESC-MSC group 
(Fig. 6E) compared with 1 week after transplantation 
(310 ± 40/mm2 vs. 45 ± 8/mm2, p < 0.01). Interestingly, 
many of anti-HNA-positive cells observed in the 
hESC-MSC group were integrated into pulmonary 
vessels (Fig. 6E, ii) while some were generally distrib-
uted in extravascular parenchyma (Fig. 6E). However, 
at 3 weeks after transplantation, no anti-HNA-positive 
cells were detected in the BM-MSC group (Fig. 6F). 
Furthermore, some engrafted hESC-MSCs (Fig. 6G) 
in small pulmonary vessels were immunoactive for 
both HNA and endothelial marker CD31, indicating 
endothelial differentiation of hESC-MSCs in injured 
lung tissue. Similarly, PCR analysis showed human 
DNA repeat sequences Alu-sx were detectable only 
in lung tissue from the hESC-MSC group but not the 
BM-MSC group (Fig. 6H). In addition, weak expres-
sion of human-specific genes FGF2, vWF, and VEGF 
were detectable in lung tissue from the hESC-MSC 
group but not the BM-MSC group (Fig. 6I). Indeed, 
a greater potential of endothelial differentiation in 
hESC-MSCs (derived from hES-3) was also confirmed 
by qRT-PCR for human endothelial progenitor marker, 
Flk-1 (Fig. 1E). These findings indicate that hESC-
MSCs are superior to adult BM-MSCs with regard to 
a long-term survival and differentiation capacity in an 
injured lung environment. 
To closely mimic clinical practice, the transplanted 
cells were administrated via intravenous injection into 
wild-type mice after immunosuppression in this study. To 
exclude the possibility that poor survival of transplanted 
cells was due to immune rejection, despite the fact that 
MSCs are thought to possess immune privilege (11), we 
intravenously delivered the same amount of BM-MSCs 
into mice with severe combined immunodeficiency. At 1 
and 3 weeks of posttransplantation, we observed a signif-
icantly decreased number of cell retention (Fig. 6J, i–ii), 
similar to previous reports (20,42). 
Paracrine Effects of MSCs 
The differences of paracrine effects between hESC-
MSCs and BM-MSCs were investigated. Following 
exposure of BM-MSCs or hESC-MSCs to serum-
free conditioned medium for 48 h, supernatants were 
collected and screened for 507 human proteins using 
RayBio® Cytokine Antibody Arrays. Our results dem-
onstrated that both hESC-MSCs and BM-MSCs were 
able to release a wide spectrum of proteins, includ-
ing cytokines, chemokines, adipokines, growth fac-
tors, angiogenic factors, and soluble receptors. Pair-wise 
comparison of the protein profiling of hESC-MSC- 
and BM-MSC-conditioned medium revealed many 
common characteristics but some distinct differences 
in paracrine factor profiling. Overall, 398 of 507 fac-
tors were commonly detected in both hESC-MSCs 
and BM-MSCs with <2.0-fold difference. Classification 
of these factors into bioprocesses disclosed that these 
secreted factors were involved in metabolism, immu-
nity, and tissue differentiation including vascularization 
and hematopoiesis. Nonetheless 68 of 507 protein fac-
tors were preferentially overpresented in hESC-MSCs 
(>2.0-fold difference, with the remaining 52 factors pref-
erentially overrepresented in BM-MSCs (>2.0-fold 
difference). 
The top 20 protein factors overrepresented in hESC-
MSC-conditioned medium were classified into biologi-
cal processes using the NIH DAVID Pathway Analysis 
tool (13) (Table 1). Our results revealed that these protein 
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Figure 6. Retention and differentiation of hESC-MSCs in response to MCT-induced pulmonary hypertension. (A) At 1 week after 
cell transplantation, immunostaining of anti-human nuclear antigen (HNA) was detected in hESC-MSC-treated lung tissue (i–iii). 
High-magnification photographs showing HNA-positive cells were distributed throughout the pulmonary parenchyma and around 
vessel walls (ii–iii, arrows). (B) Immunostaining of HNA in BM-MSC-treated lung tissue was detected (i–iii). High-magnification 
photographs demonstrate that HNA-positive cells were distributed throughout the pulmonary parenchyma (ii) and around vessel walls 
(iii). (C) RT-PCR analysis for human multiple angiogenic and growth factors in lung tissue retrieved 1 week after MSC treatment. 
It showed expression of fibroblast growth factor 2 (FGF2), von Willebrand Factor (vWF), and vascular endothelial growth factor 
(VEGF) was detected in hESC-MSC- or BM-MSC-treated mice but was undetectable in those without MSC treatment. (D) Bio-Plex 
cytokine assays show differential contents of human-specific FGF2, stem cell factor (SCF), and VEGF proteins detectable between 
BM-MSC- and hESC-MSC-treated lung tissue 1 week after cell transplantation (*p < 0.05 vs. BM-MSC group, n = 3). (E) At 3 weeks 
after cell transplantation, HNA-positive cells in hESC-MSC-treated lung tissue were detectable (i–iii). High-magnification photo-
graphs show that many of the HNA-positive cells were integrated into pulmonary vessels (ii). (F) At 3 weeks after cell transplantation, 
HNA-positive cells could not be detected in BM-MSC-treated lung tissue. (G) Some hESC-MSCs were immunoreactive for both anti-
HNA and anti-endothelial marker CD31 in small pulmonary vessels (arrows). (H) At 3 weeks after cell transplantation, genomic DNA 
analysis by PCR for the presence of human Alu-sx and mouse c-mos repeat sequences between hESC-MSC- and BM-MSC-treated 
lung tissues. MEF, mouse embryonic fibroblast cells; hFB, human fibroblast cells. (I) RT-PCR analysis from lung tissue retrieved 3 
weeks after cell transplantation shows positive expression of human FGF2, vWF, and VEGF in hESC-MSCs but not in BM-MSCs or 
MCT treated lung tissue. (J) The representative microphotographs showing immunoactivity of HNA in BM-MSC-treated lung tissues 
retrieved at week 1 (i) and week 3 (ii) after BM-MSC transplantation in SCID mice. Scale bars: 50 mm [A (i), B (i), E (i), F, G, J (i)], 
20 mm [A (ii, iii), B (ii, iii)], and 100 mm [J (ii)].
Figure 7. Differential paracrine factor profiling between hESC-MSCs and BM-MSCs secretome. (A, B) Functions and pathways 
involved in paracrine factor-related genes in hESC-MSCs (A) or BM-MSCs (B) with the NIH DAVID Pathway Analysis tool. 
Enriched functions and pathways with DAVID cluster score > 3.0 were shown in the figure. The p values were corrected using the 
Benjamin–Hochberg multiple testing method (5). (C) Quantitative Bio-Plex cytokine assays confirmed human platelet-derived growth 
factor BB (PDGFBB), VEGF, and angiogenin (ANG) were overpresented in hESC-MSC versus BM-MSC supernatants (*p < 0.01 vs. 
BM-MSCs).
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Table 1. Top 20 Proteins Overrepresented in Human Embryonic Stem 
Cell-Derived Mesenchymal Stem Cells (ESC-MSCs) Versus Bone 
Marrow-Derived MSCs (BM-MSCs) Detected by Antibody Array
hESC-MSCs BM-MSCs Ratio
EDG-1 289311.35 2541.99 113.81
PDGF-D 10588.81 132.90 79.67
FGF-10/KGF-2 2099.39 42.22 49.73
CCR1 6863.05 157.49 43.58
TWEAK/TNFSF12 4745.06 118.85 39.93
VE-cadherin 20880.95 551.27 37.88
WIF-1 41664.91 1245.51 33.45
EMAP-II 3201.55 98.39 32.54
TIMP-4 8398.55 266.73 31.49
TNF-a 16418.99 601.90 27.28
XEDAR 21299.31 816.58 26.08
VEGF-B 5022.79 194.52 25.82
AR (amphiregulin) 6003.22 292.26 20.54
VEGI/TNFSF15 32015.66 1632.03 19.62
TSLP 5609.80 291.76 19.23
WISP-1/CCN4 15659.29 817.04 19.17
TGF-b RIIb 3534.60 185.37 19.07
SonicHedgehog 
(ShhNtermial)
5641.95 300.33 18.79
PDGF-C 13830.66 780.76 17.71
Angiogenin 2719.81 156.39 17.39
Table 2. Top 20 Proteins Overrepresented in BM-MSCs Versus  
hESC-MSCs Detected by Antibody Array
BM-MSCs hESC-MSCs Ratio
HRG-a 7605.38 240.13 31.67
HRG-b1 9581.60 381.50 25.12
LRP-6 1890.50 83.46 22.65
L-selectin (CD62L) 2667.12 121.14 22.02
IL-1 F10/IL-1HY2 6748.74 406.21 16.61
Leptin (OB) 1981.29 130.02 15.24
ICAM-2 3935.04 290.83 13.53
Activin A 21648.15 1615.67 13.40
Insulysin/IDE 1245.79 99.63 12.50
IGF-II R 5506.70 452.24 12.18
IL-21 1564.85 163.71 9.56
Lefty-A 1506.56 182.23 8.27
IL-12 Rb1 3605.13 447.20 8.06
ICAM-3 (CD50) 2252.91 288.33 7.81
LECT2 1826.05 235.92 7.74
IL-22 BP 2159.10 292.88 7.37
Leptin R 1509.12 212.65 7.10
Luciferase 3904.02 633.30 6.16
Dtk 26062.63 4329.34 6.02
I-309 1717.11 294.06 5.84
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factors from hESC-MSCs are associated with early embry-
onic development, such as embryogenesis, blood vessel 
morphogenesis, and cell migration (Fig. 7A). Protein fac-
tors overrepresented in BM-MSC-conditioned medium 
(Table 2) are nonetheless associated with late embryonic 
development, such as extracellular protein synthesis, 
muscle/ skin development and immune response (Fig. 7B). 
Selected important human cytokines were quantita-
tively measured in MSC-conditioned medium using Bio-
Plex cytokine assays. Similar to the results of cytokine 
arrays, human originated angiogenin, platelet-derived 
growth factor BB, and VEGF were very prevalent in 
hESC-MSC-conditioned medium compared with those 
from BM-MSC-conditioned medium (Fig. 7C). These 
observations demonstrate that the differential profile 
of paracrine factors from hESC-MSCs and BM-MSCs 
might account for some of the differences in their thera-
peutic effect in response to MCT-induced PAH.
DISCUSSION
The results of this study confirm the previous findings 
(3,37) that MSC transplantation can attenuate elevated 
RVSP and adverse RV remodeling in an animal model of 
MCT-induced PAH and provide mechanistic insight into 
their potential beneficial effects. More importantly, our 
results at the first time demonstrate that hESC-derived 
MSCs are superior to adult BM-derived MSCs in attenu-
ation of MCT-induced pulmonary vascular remodeling 
and endothelial damage. Compared with BM-MSCs, 
hESC-MSCs derived from early embryonic stages dis-
play better survival capacity, more tolerance in an injured 
lung environment, and wider spectrum of paracrine fac-
tors to improve their therapeutic efficacy in attenuation of 
MCT-induced PAH. 
Recent experimental studies have suggested that MSC 
transplantation is a potential novel therapy for a variety of 
cardiovascular diseases including myocardial infarction 
and pulmonary hypertension (11,25,41). In clinical stud-
ies (11), adult BM-derived MSCs have been commonly 
employed, as they are widely available and relatively sim-
ple to prepare. Additionally, it has been shown that using 
MSCs achieves better results than hematopoietic precur-
sors in the treatment of myocardial infarction (2). Although 
hESC-MSCs and BM-MSCs share many common mesen-
chymal properties, hESC-MSCs are more proliferative and 
have a more robust differentiation potential in vivo (21). 
It has been proposed that MSCs derived from embryonic 
stage, that is, ESCs, respond better to ischemia with regard 
to their paracrine potential (23,38,39). This phenomenon is 
consistent with the observation that MSCs from younger 
donors or developmentally less mature tissues exhibit 
more proliferative and differentiation potential and thus 
resulted in greater therapeutic effects (10). Nevertheless, 
a comparison of BM-MSCs versus hESC-MSCs in the 
treatment of cardiovascular disease has not been studied. 
In this study, we compared the potential therapeutic effi-
cacy of MSCs derived from hESC lines with those derived 
from adult BM in the treatment of PAH. Compared with 
BM-MSCs, hESC-MSCs more effectively attenuated MCT-
induced occlusive wall thickness of pulmonary arterioles, 
elevated RVSP, and adverse RV remodeling. Survival of 
the transplanted stem cells including MSCs remains a criti-
cal factor in the success of cell-based therapy (9,20,41). 
Previous studies have shown a poor long-term retention 
of MSCs in injured heart (1,28) and lung tissue (33,42) 
after 3–6 weeks of posttransplantation. Our results showed 
that hESC-MSCs had better tolerance and higher survival 
potential than BM-MSCs. Although only a small number 
of transplanted hESC-MSCs remained detectable in lung 
tissues at 3 weeks after transplantation, no transplanted 
BM-MSCs were detected at 3 weeks after transplantation. 
Nevertheless, the relatively low rate of cell engraftment 
and the inefficiency of the transplanted MSCs to differenti-
ate into functional reparative cells in injured tissue do not 
account for the therapeutic effects of MSC transplantation 
observed in this study. Prior studies (9,17,31) have suggested 
that paracine effects rather than de novo vascular regenera-
tion of MSCs may play a more important role in vascular 
repair and protection. In this study, we observed local expres-
sion of human cytokines and growth factors are consistent 
with the persistence of the transplanted cells. These find-
ings suggest that transplanted MSCs release cytokines in 
response to MCT-induced injury of the pulmonary vascu-
lature. In addition, using antibody arrays, we demonstrated 
both similarities as well as differences in the paracrine pro-
files between hESC-MSCs and BM-MSCs, which might 
differentially contribute to amelioration of PAH. Analysis 
of the proteome secretion of hESC-MSCs revealed unique 
factors that are involved in the biological processes of anti- 
inflammation, cell survival, proliferation, and differentiation. 
Some cytokines and growth factors have been shown to be 
important in cardiovascular protection, such as angiogenin, 
VEGF, stromal-derived factor (40,45), secreted frizzled 
related protein (27), interleukin-10 (6), and matrix metallo-
proteinase-9 (17). These differential paracrine factors released 
from hESC-MSCs may account for the better survival of the 
transplanted MSCs and their superior therapeutic efficacy to 
BM-MSCs for pulmonary vascular protection and repair.
Study Limitations
This study has several limitations. In this study, a mice 
model of MCT-induced PAH was used rather than the more 
characterized model in rat. Compared with rat, mice are less 
susceptible to MCT-induced PAH. Nevertheless, we have 
tested three different doses of MCT and confirmed the suc-
cessful creation of PAH in MCT with an optimal dose of 
400 mg/kg MCT as reported previously (36). Second, the 
results of this study may not be applicable to other animal 
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models of PAH, such as those induced by other toxic agents 
(e.g., blemycin), molecular stimuli, or hypoxia condition. 
Indeed, different results have been reported from different 
animal models of PAH with regard to the therapeutic effi-
cacy of MSC transplantation (32,33). However, none of the 
currently available animal models can completely recapitu-
late the entire pathogenesis of PAH in human (8,35). Final 
MSC transplantation was performed in the early phase of 
PAH, and the therapeutic efficacy of MSC transplantation 
in a later phase of PAH remains unclear. 
Conclusions
Taken together, our results demonstrate that pluripo-
tent hESC-derived MSCs are superior to adult BM-MSCs 
in attenuation of MCT-induced PAH in an animal model. 
Compared to BM-MSCs, a greater potential of hESC-MSCs 
in PAH treatment may be attributed to a higher capacity of 
cell survival and more prominent paracrine effects.
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